BACKGROUND: In X-linked adrenoleukodystrophy, mutations in ABCD1 lead to loss of function of the ALD protein. Cerebral adrenoleukodystrophy is characterized by demyelination and neurodegeneration. Disease progression, which leads to loss of neurologic function and death, can be halted only with allogeneic hematopoietic stem-cell transplantation. METHODS: We enrolled boys with cerebral adrenoleukodystrophy in a single-group, open-label, phase 2-3 safety and efficacy study. Patients were required to have early-stage disease and gadolinium enhancement on magnetic resonance imaging (MRI) at screening. The investigational therapy involved infusion of autologous CD34+ cells transduced with the elivaldogene tavalentivec (Lenti-D) lentiviral vector. In this interim analysis, patients were assessed for the occurrence of graft-versus-host disease, death, and major functional disabilities, as well as changes in neurologic function and in the extent of lesions on MRI. The primary end point was being alive and having no major functional disability at 24 months after infusion. RESULTS: A total of 17 boys received Lenti-D gene therapy. At the time of the interim analysis, the median follow-up was 29.4 months (range, 21.6 to 42.0). All the patients had gene-marked cells after engraftment, with no evidence of preferential integration near known oncogenes or clonal outgrowth. Measurable ALD protein was observed in all the patients. No treatment-related death or graft-versus-host disease had been reported; 15 of the 17 patients (88%) were alive and free of major functional disability, with minimal clinical symptoms. One patient, who had had rapid neurologic deterioration, had died from disease progression. Another patient, who had had evidence of disease progression on MRI, had withdrawn from the study to undergo allogeneic stem-cell transplantation and later died from transplantation-related complications. CONCLUSIONS: Early results of this study suggest that Lenti-D gene therapy may be a safe and effective alternative to allogeneic stem-cell transplantation in boys with early-stage cerebral adrenoleukodystrophy. Additional follow-up is needed to fully assess the duration of response and long-term safety. (Funded by Bluebird Bio and others; STARBEAM ClinicalTrials.gov number, NCT01896102 ; ClinicalTrialsRegister.eu number, 2011-001953-10 .).
BACKGROUND: In X-linked adrenoleukodystrophy, mutations in ABCD1 lead to loss of function of the ALD protein. Cerebral adrenoleukodystrophy is characterized by demyelination and neurodegeneration. Disease progression, which leads to loss of neurologic function and death, can be halted only with allogeneic hematopoietic stem-cell transplantation. METHODS: We enrolled boys with cerebral adrenoleukodystrophy in a single-group, open-label, phase 2-3 safety and efficacy study. Patients were required to have early-stage disease and gadolinium enhancement on magnetic resonance imaging (MRI) at screening. The investigational therapy involved infusion of autologous CD34+ cells transduced with the elivaldogene tavalentivec (Lenti-D) lentiviral vector. In this interim analysis, patients were assessed for the occurrence of graft-versus-host disease, death, and major functional disabilities, as well as changes in neurologic function and in the extent of lesions on MRI. The primary end point was being alive and having no major functional disability at 24 months after infusion. RESULTS: A total of 17 boys received Lenti-D gene therapy. At the time of the interim analysis, the median follow-up was 29.4 months (range, 21.6 to 42.0). All the patients had gene-marked cells after engraftment, with no evidence of preferential integration near known oncogenes or clonal outgrowth. Measurable ALD protein was observed in all the patients. No treatment-related death or graft-versus-host disease had been reported; 15 of the 17 patients (88%) were alive and free of major functional disability, with minimal clinical symptoms. One patient, who had had rapid neurologic deterioration, had died from disease progression. Another patient, who had had evidence of disease progression on MRI, had withdrawn from the study to undergo allogeneic stem-cell transplantation and later died from transplantation-related complications. CONCLUSIONS: Early results of this study suggest that Lenti-D gene therapy may be a safe and effective alternative to allogeneic stem-cell transplantation in boys with early-stage cerebral adrenoleukodystrophy. Additional follow-up is needed to fully assess the duration of response and long-term safety. (Funded by Bluebird Bio and others; STARBEAM ClinicalTrials.gov number, NCT01896102 ; ClinicalTrialsRegister.eu number, 2011-001953-10 .).
Authors: Lynda E Polgreen; Saydi Chahla; Weston Miller; Steven Rothman; Jakub Tolar; Teresa Kivisto; David Nascene; Paul J Orchard; Anna Petryk Journal: Eur J Pediatr Date: 2011-01-29 Impact factor: 3.183
Authors: Weston P Miller; Steven M Rothman; David Nascene; Teresa Kivisto; Todd E DeFor; Richard S Ziegler; Julie Eisengart; Kara Leiser; Gerald Raymond; Troy C Lund; Jakub Tolar; Paul J Orchard Journal: Blood Date: 2011-05-17 Impact factor: 22.113
Authors: Björn M van Geel; Bwee Tien Poll-The; Aad Verrips; Jaap-Jan Boelens; Stephan Kemp; Marc Engelen Journal: J Inherit Metab Dis Date: 2014-12-09 Impact factor: 4.982
Authors: D J Loes; S Hite; H Moser; A E Stillman; E Shapiro; L Lockman; R E Latchaw; W Krivit Journal: AJNR Am J Neuroradiol Date: 1994-10 Impact factor: 3.825
Authors: Donald Beam; Michele D Poe; James M Provenzale; Paul Szabolcs; Paul L Martin; Vinod Prasad; Suhag Parikh; Tim Driscoll; Srini Mukundan; Joanne Kurtzberg; Maria L Escolar Journal: Biol Blood Marrow Transplant Date: 2007-04-06 Impact factor: 5.742
Authors: Devesh C Pant; Imen Dorboz; Agatha Schluter; Stéphane Fourcade; Nathalie Launay; Javier Joya; Sergio Aguilera-Albesa; Maria Eugenia Yoldi; Carlos Casasnovas; Mary J Willis; Montserrat Ruiz; Dorothée Ville; Gaetan Lesca; Karine Siquier-Pernet; Isabelle Desguerre; Huifang Yan; Jingmin Wang; Margit Burmeister; Lauren Brady; Mark Tarnopolsky; Carles Cornet; Davide Rubbini; Javier Terriente; Kiely N James; Damir Musaev; Maha S Zaki; Marc C Patterson; Brendan C Lanpher; Eric W Klee; Filippo Pinto E Vairo; Elizabeth Wohler; Nara Lygia de M Sobreira; Julie S Cohen; Reza Maroofian; Hamid Galehdari; Neda Mazaheri; Gholamreza Shariati; Laurence Colleaux; Diana Rodriguez; Joseph G Gleeson; Cristina Pujades; Ali Fatemi; Odile Boespflug-Tanguy; Aurora Pujol Journal: J Clin Invest Date: 2019-02-11 Impact factor: 14.808
Authors: Cristina Puig-Saus; Giulia Parisi; Angel Garcia-Diaz; Paige E Krystofinski; Salemiz Sandoval; Ruixue Zhang; Ameya S Champhekar; James McCabe; Gardenia C Cheung-Lau; Nhat A Truong; Agustin Vega-Crespo; Marie Desiles S Komenan; Jia Pang; Mignonette H Macabali; Justin D Saco; Jeffrey L Goodwin; Brad Bolon; Christopher S Seet; Amelie Montel-Hagen; Gay M Crooks; Roger P Hollis; Beatriz Campo-Fernandez; Daniela Bischof; Kenneth Cornetta; Eric H Gschweng; Celia Adelson; Alexander Nguyen; Lili Yang; Owen N Witte; David Baltimore; Begonya Comin-Anduix; Donald B Kohn; Xiaoyan Wang; Paula Cabrera; Paula J Kaplan-Lefko; Beata Berent-Maoz; Antoni Ribas Journal: Clin Cancer Res Date: 2018-11-08 Impact factor: 12.531
Authors: Jieru E Lin; Eric A Armour; Arezou Heshmati; Christine Umandap; Julia J Couto; Alejandro D Iglesias; Eric J Mallack; Jennifer M Bain Journal: Neurology Date: 2019-07-09 Impact factor: 9.910
Authors: Quentin Raas; Malu-Clair van de Beek; Sonja Forss-Petter; Inge Me Dijkstra; Abigail Deschiffart; Briana C Freshner; Tamara J Stevenson; Yorrick Rj Jaspers; Liselotte Nagtzaam; Ronald Ja Wanders; Michel van Weeghel; Joo-Yeon Engelen-Lee; Marc Engelen; Florian Eichler; Johannes Berger; Joshua L Bonkowsky; Stephan Kemp Journal: J Clin Invest Date: 2021-04-15 Impact factor: 14.808
Authors: Sara E Grineski; Danielle X Morales; Timothy Collins; Jacob Wilkes; Joshua L Bonkowsky Journal: J Racial Ethn Health Disparities Date: 2020-02-24